duligotuzumab (MEHD7945A) - Roche
Roche: HY 2014 Results (Roche) - Jul 26, 2014 - Anticipated NME submission in US for metastatic epithelial tumors in 2017 or later; Anticipated NME submission in EU for metastatic epithelial tumors in 2017 or later 
Anticipated EU regulatory • Anticipated NDA Oncology
http://www.roche.com/investors/ir_agenda/halfyear-2014.htm
 
Jul 26, 2014
 
.
 
4a65d555-cc0a-410d-b77f-99ed64221833.jpg